Ocular Diseases and Behçet’s Syndrome
Research Guide

The International Study Group criteria for Behçet's disease require recurrent oral ulcers plus two of: recurrent genital ulcers, eye lesions, skin lesions, or positive pathergy test, as established in "Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease." (1990). These criteria resolved inconsistencies among prior sets used in research. They enable reliable diagnosis for clinical trials and management.

Uveitis nomenclature is standardized through anatomical, clinical, and etiologic classifications from the First International Workshop, detailed in "Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop" by Douglas A. Jabs et al. (2005). This system ensures uniform reporting of clinical data. It supports comparability across studies on inflammatory eye diseases.

Behçet's disease features recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions, with uveitis risking blindness from repeated attacks, per "Behçet's Disease" by Tsuyoshi Sakane et al. (1999). Ocular involvement is self-limiting per attack but cumulative. Management targets inflammation to preserve vision.

Therapies include immunosuppressive drugs, anti-TNF therapy, and interferon alpha2a for uveitis in Behçet's disease, as covered in the field description. These address inflammatory eye diseases like choroiditis. They aim to control recurrence and prevent vision loss.

Epidemiology examines prevalence and patterns of uveitis and Behçet's disease, including associations with juvenile idiopathic arthritis. Papers track regional variations and risk factors. This informs targeted diagnosis and public health strategies.